Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
- Conditions
- Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with advanced endometrial cancerMedDRA version: 21.0Level: PTClassification code 10014733Term: Endometrial cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10014734Term: Endometrial cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10014736Term: Endometrial cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2017-000607-25-DE
- Lead Sponsor
- Karyopharm Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- Female
- Target Recruitment
- 192
1.Female, at least 18 years of age at the time of informed consent.
2.Histological confirmed endometrial cancer of the endometrioid, serous, or undifferentiated type. Carcinosarcoma of the uterus is also allowed.
3.Completed a single line of at least 12 weeks of taxane-platinum combination therapy for Stage IV disease or at first relapse and is in partial or complete remission according to RECIST v1.1. This includes patients who received taxane-platinum combination therapy for primary Stage IV disease and patients who received taxane-platinum combination therapy for recurrent (i.e., relapse after primary therapy for early stage disease including surgery and/or adjuvant therapy) disease.
4.Must be able to initiate study drug 5 to 8 weeks after completion of their final dose of chemotherapy.
5.Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
6.Patients must have adequate bone marrow function and organ function within 2 weeks before starting study drug as defined by the following laboratory criteria:
a. Hepatic function: total bilirubin up to 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =2.5 x ULN in patients without liver metastasis. For patients with known liver involvement of their tumor: AST and ALT =5 x ULN.
b. Hematopoetic function: Absolute neutrophil count (ANC) =1.5 x 109/L; platelet count =100 x 109L; hemoglobin =9.0 g/dL.
c. Renal function: estimated creatinine clearance (CrCl) of =30 mL/min, calculated using the Cockroft-Gault formula.
7.In the opinion of the Investigator, the patient must:
a.Have a life expectancy of at least 12 weeks, and
b.Be fit to receive experimental therapy
8.Premenopausal females of childbearing potential must have a negative pregnancy test (serum ß human chorionic gonadotropin test) prior to the first dose of study drug. Female patients of childbearing potential must agree to use must agree to use highly effective methods of contraception throughout the study and for 3 months following the last dose of study drug.
9.Written informed consent in accordance with federal, local, and institutional guidelines. The patient must provide informed consent prior to the first screening procedure.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 132
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range 60
1.Has any sarcomas, small cell carcinoma with neuroendocrine differentiation, or clear cell carcinomas.
2.Received a blood or platelet transfusion during 4 weeks prior to randomization.
3.Being treated with a concurrent cancer therapy.
4.Previous treatment with an XPO1 inhibitor.
5. Previous treatment with anti-PD1 or anti-PD-L1 immunotherapy (e.g., pembrolizumab).
6. Concurrent treatment with an investigational agent or participation in another clinical trial.
7. Patients who received any systemic anticancer therapy including investigational agents or radiation =3 weeks (or =5 half-lives of the drug [whichever is shorter]) prior to C1D1. Palliative radiotherapy may be permitted for symptomatic control of pain from bone metastases in extremities, provided that the radiotherapy does not involve target lesions, and the reason for the radiotherapy does not reflect progressive disease (PD).
8. Major injuries or surgery within 14 days prior to C1D1 and/or planned surgery during the on-treatment study period.
9.Previous malignant disease, except patients with other malignant disease, for which the patient has been disease-free for at least 3 years. Concurrent other malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin.
10.Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient’s safety or compliance with the protocol.
11.Known contraindications to selinexor.
12.Known uncontrolled hypersensitivity to the investigational drug, or to its excipients.
13.Radiotherapy to the target lesion within the past 3 months prior to baseline imaging.
14.Persistent Grade 3 or 4 toxicity from previous chemotherapy and/or radiotherapy, with the exception of alopecia.
15.Active brain metastases (e.g., stable for <8 weeks, no adequate previous treatment with radiotherapy and/or surgery, symptomatic, requiring treatment with anti-convulsants. Corticoid therapy is allowed if administered as stable dose for at least 1 month before randomization).
16.Known unstable cardiovascular function:
a. Symptomatic ischemia, or
b. Uncontrolled clinically significant conduction abnormalities (i.e., ventricular tachycardia on anti-arrhythmia are excluded; 1st degree atrioventricular block or asymptomatic left anterior fascicular block /right bundle branch block will not be excluded), or
c. Congestive heart failure of New York Heart Association Class =3, or
d. Myocardial infarction within 3 months
17.Females who are pregnant or actively breastfeeding.
18.Uncontrolled (i.e., clinically unstable) infection requiring parenteral antibiotics, antivirals, or antifungals within 1 week prior to first dose; however, prophylactic use of these agents is acceptable even if parenteral.
19.Active hepatitis C and/or B infection.
20.Patients unable to swallow tablets, patients with malabsorption syndrome, or any other GI disease or GI dysfunction that could interfere with absorption of study drug. A history of bowel obstruction requiring a nasogastric tube or intravenous infusion during the past 2 months is not allowed (except when this obstruction is caused by surgery or other non-malignant causes).
21.Psychiatric illness or substance use that would prevent the patient from giving informed consent or being compliant with the study procedures.
22.Patients unwilling or unable to comply with the protocol.
23.Persons who have b
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method